Linked Life Data

6100614

Source:http://linkedlifedata.com/resource/pubmed/id/6100614

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-2-18
pubmed:abstractText
The renal effects of the new angiotensin converting enzyme inhibitor enalapril (MK-421) and of its active metabolite MK-422, were investigated in patients with essential hypertension. Together with a reduction in blood pressure, renal blood flow increased after intravenous injection of MK-422. Glomerular filtration as well as fractional sodium excretion increased. The latter was explained by the inhibition of both proximal and distal tubular sodium reabsorption. During oral enalapril therapy renal blood flow remained elevated, whereas glomerular filtration did not differ significantly from pretreatment values. Body weight fell after 12 weeks of therapy, a possible consequence of the 'diuretic' effect of enalapril which may contribute to the antihypertensive action of the drug. In conclusion, enalapril had either no, or even beneficial, effects on renal function.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0952-1178
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
93-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
The angiotensin converting enzyme inhibitor enalapril and its effects on renal function.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't